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ments. However, these drugs show slow onset of action and limited 
efficacy, making necessary the use of drug augmentation strategies 
or more aggressive interventions. Two important observations have 
emerged in recent years indicating that more rapid and effective 
antidepressant treatments are possible. On the one hand, the deep 
brain stimulation (DBS) of ventral anterior (subgenual) cingulate 
cortex (Cg25) evokes rapid mood improvements in subgroups of 
treatment-resistant depressive patients, likely mediated by a func-
tional remodeling of cortico-limbic circuits. On the other hand, the 
noncompetitive NDMA receptor antagonist ketamine can also evoke 
raid (eg, 2 hours) and persistent (up to 1 week) improvements in some 
treatment-resistant patients. Moreover, recent preclinical observa-
tions indicate the antidepressant capacity of nGluR agents. Overall, 
this supports the usefulness of glutamatergic transmission as a new 
area in antidepressant drug development. On the monoamine side, 
new preclinical and clinical research should clarify the different roles 
played by 5-HT receptors in depression as well as the brain areas and 
circuits responsible for therapeutic improvement. This will lead to the 
synthesis of new agents blocking the serotonin (and possibly norepi-
nephrine) transporter, which will also activate or block 5-HT recep-
tors playing, respectively, positive (eg, postsynaptic 5-HT1A, 5-HT4) 
or negative (eg, presynaptic 5-HT1A,/1B, 5-HT2A, 5-HT2C,5-HT3) 
roles in antidepressant effects.
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Summary: Intravenous fat emulsion (IFE) has been used as an 
antidote and is most extensively studied for the treatment of local 
anesthetic toxicity. New applications beyond local anesthetic are pro-
posed, including calcium channel blockers, cyclic antidepressants, 
clomipramine, and β -adrenergic antagonists. There are 3 proposed 
mechanisms of action of IFE in toxicology: modulation of intra-
cellular metabolism, a lipid sink or sponge mechanism, and activa-
tion of ion channels. The lipid sink/sponge model is the most likely 
mechanism. Several experimental models demonstrate the benefit of 
IFE in bupivacaine, calcium channel blockers, cyclic antidepressants, 
and β -adrenergic antagonist toxicity. Multiple case reports using IFE 
in a variety of drug toxicity report improvement. Potential adverse 
effects may limit use but have been reported infrequently, and the 
benefit of IFE may outweigh potential risks. The dose, timing of 
administration, and the uses and comparison with other treatments 
are in need of future studies. The recommended dose of 20% IFE is a 
1.5-mL/kg bolus followed by 0.25 mL/kg/min or 15 mL/kg/h to run 
for 30 to 60 minutes. The bolus can be repeated several times for 
persistent asystole, and the infusion rate can be increased if blood 
pressure decreases.
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Summary: Paracetamol poisoning was first reported > 45 years ago, 
but its optimum management is still a matter of debate. In part this 
is because of the difficulty in precise risk stratification early in poi-
soning and a lack of effective antidotal treatments for those who 
present late after ingestion. National drug regulatory and poisons 
information systems in different countries provide different advice, 
and the United Kingdom changed its risk stratification advice in 2012 
after > 30 years. Observational data suggest that repeated ingestions 
of lower doses may cause more severe liver damage than a single 
ingestion, but the reasons for this remain unclear. The antidote IV 
acetylcysteine is given in a complex dose regimen that is not tailored 
to the amount of toxin ingested, and the initial duration of antidote 
therapy was determined empirically in the mid-1970s. Adverse effects 
to the antidote acetylcysteine are a further challenge, as they are more 
frequent at lower paracetamol concentrations.
We have recently been able to establish a population estimate of 
risk, which shows that early presentation managed conventionally 
results in good outcome and that mortality is almost always in those 
presenting > 15 hours after first ingestion. Co-ingestion of other drugs 
that delay gastric motility and the introduction of modified-release 
paracetamol products further complicate management approaches, 
and the safety of marketing of SR preparations must be questioned 
from a public health perspective. New biomarkers offer the potential 
to better identify patients who are at specific risk, and appear to pre-
cede, and better predict, than rises in the traditional transaminases. 
Newer, modified acetylcysteine regimens should improve its safety 
profile. Linked to new biomarkers, these potentially offer shorter 
durations of hospital stay for paracetamol overdose.
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Summary: Progress in the treatment of inborn errors of metabolism 
has derived from insight into their causes and has focused on nutri-
tional limitation of a substrate or replacement of missing products, 
the removal of toxic metabolites and maximizing anabolism, or com-
pensatory expression of a protein whose deficiency causes disease 
through stem cell or organ transplantation.
The knowledge of the biochemistry and the pathway of lysosomal 
enzymes and the concept of systemic delivery of a deficient enzyme 
carrying a mannose-6-phosphate residue that serves as recognition 
marker for both uptake and transport to lysosomes resulted in the 
first successful enzyme replacement therapies in patients with lyso-
somal storage disorders.
The use of small molecules as therapeutic agents is another 
approach that is being applied widely to inborn errors of metabolism. 
This is illustrated by substrate reduction therapy, which has shown 
to be effective in some lysosomal storage disorders and complements 
some of the limitations of enzyme-replacement therapy (eg, crossing 
the blood-brain barrier). Pharmacologic chaperones generally bind 
directly to mutant proteins and mediate improvement in the folding, 
the transport, or the stability and hence elevated levels of mutant 
protein with residual function. One example for this is treatment 
with pharmacologic doses of cofactor or cofactor analogues such as 
in phenylketonuria. Other novel therapeutic approaches include the 
use of “old” approved drugs to compensate for functional deficits or 
antagonize unwanted effects. One example is the use of losartan to 
reduce TGF-b activity in Marfan’s syndrome and other genetically 
caused forms of aortic aneurysm.
Finally, new developments will be discussed such as manipulation 
of gene expression by suppression of nonsense-mediated decay or 
manipulation of pre-mRNA splicing using short oligonucleotides. 
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These include siRNA and microRNA used to degrade mRNA tran-
scripts and suppress protein translation, and antisense oligonucleo-
tides used to manipulate splicing.
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Summary: The use of vitamin K antagonists (VKA) is challenging 
because of their narrow therapeutic index and a large interindividual 
variability. Pauci data were available regarding the relative contribu-
tion of pharmacogenetic and nongenetic factors to VKA response 
in specific populations (elderly, children, resistant patients). In 2 
cohorts of elderly patients receiving warfarin (n = 300) or fluin-
dione (n = 156), genetic factors were the main determinants of the 
maintenance dose, explaining ~20% of the variability versus ~10% 
for nongenetic factors. The variables significantly associated with the 
maintenance dose were VKORC1/CYP2C9/CYP4F2/EPHX1 and age 
for warfarin, and VKORC1/ABCB/CYP4F2, weight, and amiodar-
one intake for fluindione by multivariate analysis. During warfarin 
initiation, VKORC1 genotype had a strong predictive value for war-
farin sensitivity. When building prediction models of the warfarin 
dose, VKORC1/CYP2C9 were the best predictors before initiation, 
whereas their contribution was negligible once INR value was avail-
able after starting warfarin using a standardized regimen.
In the children cohort (n = 120), height and VKORC1/CYP2C9 
were the main determinants of warfarin dose requirement, explaining 
70% of the variability accounting for 48% and 20%, respectively.
Among the 100 patients resistant referred to us for analysis, only 
30 patients were carriers of VKORC1 mutations for which in vitro 
functional characterization was performed. Our results suggest the 
involvement of other genetic factors in VKA resistance.
Pharmacogenetics will help the development of personalized med-
icine to improve safety and efficacy during VKA treatment. Whether 
genetic testing improves long-term anticoagulation control in patients 
receiving VKA and prone to instability remains to be determined.
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Summary: Rapid scientific advances and tools in genomics such 
as in the light of epigenomics, microbiomics, and systems biology 
supported by new ICT solutions not only contribute to the under-
standing of disease mechanisms but also provide the option of new 
promising applications in human health management during the 
whole life-course. What was a little time ago a vision for a new era 
of public health, in which advances from the -omic sciences would 
be integrated into strategies aiming at benefiting population health, 
is now responding to the very pressing need for the development of 
effective personalized health care, going even beyond personalized 
medicine based on a systems medicine approach. Although the utility 
of most genetic tests and biomarkers is still not evidence based, the 
real take-home message stops here and is a different one. In the per-
sonalized medicine setting, the traditional assessment and evaluation 
tools just do not work anymore. Thus, we clearly face the need for 
a new paradigm moving from population health to personal health. 
The paradigm shift depends on the willingness to restructure poli-
cies, and there is a clear urgency to prepare health care systems and 
policy makers in time.
So far, all stakeholders, including policy makers and the pri-
vate sector, are struggling to translate the emerging knowledge 
into public health. Public Health Genomics (PHG) is the area of 
public health ensuring that scientific advances in genomics (“from 
cell...”) triggered by innovative technologies are timely, effectively, 
and responsibly translated into health policies and practice for the 
benefit of population health (“...to society”). The implementation of 
PHG requires increased concerted activities. The Institute for Public 
Health Genomics (IPHG) at Maastricht University aims to fulfill 
this task in all European Member States by hosting the European 
Centre for Public Health Genomics (ECPHG) and coordinating the 
Public Health Genomics European Network (PHGEN). Furthermore, 
it closely collaborates with the European Science Foundation (ESF 
Forward Look on Personalised Medicine), the European Alliance 
for Personalised Medicine (EAPM), and the European Flagship Pilot 
ITFoM on the future of medicine, being one of the most ambitious 
worldwide, large-scale, science-driven, research initiatives that aim 
to achieve the visionary goal of the “virtual human.”
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Summary: One of the core objectives of medical curricula is to provide 
graduates with a sufficient level of therapeutic knowledge and skills. 
Over the last decade, a lot has changed when it comes to teaching 
medical students how to prescribe rationally. In the Netherlands, most 
medical curricula shifted from a so-called problem-based learning to 
a context-learning pharmacotherapy program. However, there is still 
no systematic approach available for assessing students’ therapeu-
tic knowledge and skills during such a context-learning curriculum. 
Research on this topic consists almost exclusively of descriptive and 
evaluative studies on different assessment methods. These studies show 
that the often-used single-shot assessments have their shortcomings 
and poorly meet the recent developments in medical education (con-
text-learning). What is needed is a systematic approach to assessment.
In this session, David Brinkman proposes a new systematic model 
(TRACK) for assessing students’ therapeutic knowledge, skills/com-
petencies, and attitude during a context-learning curriculum. This 
longitudinal model is based on a set of assessment principles that are 
interpreted from empirical evidence. He discusses a number of chal-
lenges and opportunities around the proposed model and presents 
preliminary findings of this new project. One of its prime virtues is 
that it enables therapeutic assessment toward an assessment design 
that is underpinned by empirically grounded theory and, moreover, 
carefully follows students until they are prescribers.
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